Antibody Affinity

• 

  Subject Areas on Research

  • A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1. 
  • A murine monoclonal antibody directed against the carboxyl-terminal domain of GRP78 suppresses melanoma growth in mice. 
  • A tool for evaluating heterogeneity in avidity of polyclonal antibodies. 
  • Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. 
  • Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41. 
  • Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas. 
  • Allelic exclusion of the TCR alpha-chain is an active process requiring TCR-mediated signaling and c-Cbl. 
  • An entirely cell-based system to generate single-chain antibodies against cell surface receptors. 
  • Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. 
  • Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. 
  • Antigen drives very low affinity B cells to become plasmacytes and enter germinal centers. 
  • Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. 
  • Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. 
  • Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I. 
  • Binding of polyreactive antibodies to self versus foreign antigens. 
  • Binding specificity of a monoclonal anti-DNA antibody. 
  • Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. 
  • Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. 
  • Characterization of the binding epitope of the monoclonal antibody DMAb-1 to ganglioside GM2. 
  • Complex Antigens Drive Permissive Clonal Selection in Germinal Centers. 
  • Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. 
  • Computational analysis of antibody dynamics identifies recent HIV-1 infection. 
  • Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope. 
  • Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5. 
  • Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. 
  • Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group. 
  • Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity. 
  • Development and validation of a cell-based fluorescent method for measuring antibody affinity. 
  • Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation. 
  • Distinctive characteristics of germinal center B cells. 
  • Dynamic antibody-binding properties in the pathogenesis of HIT. 
  • Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. 
  • Enhanced differentiation of splenic plasma cells but diminished long-lived high-affinity bone marrow plasma cells in aged mice. 
  • Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. 
  • Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. 
  • Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. 
  • GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. 
  • Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. 
  • Genetic and structural analyses of affinity maturation in the humoral response to HIV-1. 
  • HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. 
  • High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A. 
  • Humoral immune responses in Cr2-/- mice: enhanced affinity maturation but impaired antibody persistence. 
  • Identification and functional analysis of human natural anti-pig xenoantibodies. 
  • Identification of deacetylase substrates with the biotin switch approach. 
  • Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. 
  • Immune recognition of DNA in SLE. 
  • Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. 
  • Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen. 
  • In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. IV. Affinity-dependent, antigen-driven B cell apoptosis in germinal centers as a mechanism for maintaining self-tolerance. 
  • In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. V. Affinity maturation develops in two stages of clonal selection. 
  • In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. 
  • Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. 
  • Intraclonal generation of antibody mutants in germinal centres. 
  • Localization of LRRK2 to membranous and vesicular structures in mammalian brain. 
  • Long-primed germinal centres with enduring affinity maturation and clonal migration. 
  • Low-Avidity Autoantibodies against Bactericidal/Permeability-Increasing Protein Occur in Gram-Negative and Gram-Positive Bacteremia. 
  • Monoclonal antibodies as molecular probes to study structural heterogeneity between human and animal renins and other aspartyl proteinases. 
  • Monoclonal antibodies binding renal renin. 
  • Mouse/human chimeric Me1-14 antibody: genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization. 
  • Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. 
  • Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. 
  • Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. 
  • PAS-C platelets contain less plasma protein, lower anti-A and anti-B titers, and decreased HLA antibody specificities compared to plasma platelets. 
  • Preparation of monoclonal antibodies reactive to the endogenous small molecule, anandamide. 
  • Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum. 
  • Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Plasmodium falciparum Circumsporozoite Protein Antigens. 
  • Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates. 
  • Rapid kinetic-based screening of human Fab fragments. 
  • Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis. 
  • Relaxed negative selection in germinal centers and impaired affinity maturation in bcl-xL transgenic mice. 
  • Selection of novel affinity-matured human chondroitin sulfate proteoglycan 4 antibody fragments by yeast display. 
  • Specificity and immunochemical properties of anti-DNA antibodies induced in normal mice by immunization with mammalian DNA with a CpG oligonucleotide as adjuvant. 
  • Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee. 
  • Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. 
  • Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. 
  • Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. 
  • Surface plasmon resonance measurements of plasma antibody avidity during primary and secondary responses to anthrax protective antigen. 
  • Synthetic nanobodies as angiotensin receptor blockers. 
  • Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. 
  • The antigenic properties of bacterial DNA in normal and aberrant immunity. 
  • The function and affinity maturation of HIV-1 gp120-specific monoclonal antibodies derived from colostral B cells. 
  • The high-affinity immunoglobulin receptor FcγRI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat. 
  • The human antibody response to the surface of Mycobacterium tuberculosis. 
  • The influence of DNA size on the binding of anti-DNA antibodies in the solid and fluid phase. 
  • The interaction of anti-DNA antibodies with DNA antigen: Evidence for hysteresis for high avidity binding. 
  • The structural basis of repertoire shift in an immune response to phosphocholine. 
  • Translating antibody-binding peptides into peptoid ligands with improved affinity and stability. 
  • What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Breaking through Immunity's Glass Ceiling. 
• 

  Keywords of People

  • Ferrari, Guido, Professor in Surgery, Molecular Genetics and Microbiology
  • Gunn, Michael Dee, Professor of Medicine, Integrative Immunobiology
  • Kelsoe, Garnett H., James B. Duke Distinguished Professor of Immunology, Integrative Immunobiology
  • McCarthy, Janice Marie, Medical Instructor in Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Sekaran, Moses, Assistant Professor in Surgery, Surgery, Surgical Sciences